NEW YORK (GBI Research), 27 April 2012 - The rising demand for innovative oral drugs is set to drive research within the delivery market, promising new formulations and more choice for consumers, according to a new report by pharmaceutical market experts GBI Research.
The new report* shows that continued growth in the demand for advancements in drug delivery is encouraging major pharmaceutical companies to continue reformulating drugs and improving upon medical favorites.
The implementation of different technologies for oral drug delivery is changing the market scenario. Pharmaceutical companies are paying this area a high level of attention, due to the advantages that such research can provide, such as reformulations able to reposition drugs and delay patent expiry while saving the company money.
The Food and Drug Administration (FDA) approves more reformulations than new chemical entities each year. The FDA approved 75 reformulations and 26 New Chemical Entities (NCEs) in 2009, which provided a valuable opportunity for pharmaceutical companies to extend the exclusivity period of a drug. The Research and Development (R&D) cost for reformulating a drug is also generally lower than for developing NCEs, which has led pharmaceutical companies to take a keen interest in this area.
This process has been a key part of large pharmaceutical companies’ drug lifecycle management protocols for more than a decade, and innovative pharmaceutical companies can expect reformulation to sustain the market value of their leading products.
Small molecules constitute the largest segment of marketed drugs, as they are generally more stable and easier to manufacture when compared to protein or peptide drugs or vaccines. Small molecule drugs for infectious diseases are most in-demand, with a 21.7% share of the market. The three next largest shares of this market are held by drugs for the Central Nervous System (CNS), with 17.5%, and cardiovascular and respiratory disorders, with 11.9% and 8.2% respectively.
The oral drug delivery market was valued at $49 billion in 2010, and is forecast to grow at a CAGR of 10.3% to reach $97 billion by 2017.
*Oral Drug Delivery Market to 2017 – Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth
This report focuses on the current scenario of orally administered drugs. Key segments of orally administered drugs covered in the report include small molecules, proteins, peptides and vaccines. The report analyses marketed oral drugs based on molecule type and indication, with pipeline drugs by molecule type discussed in detail. It also analyses different types of nano-technology, which will decide the future of orally administered drugs. Key drug delivery companies are profiled with their proprietary technologies, pipeline molecules and deals.
This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at email@example.com